J&J Enters LAA Closure Market In Earnest With Coherex Buy
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's Biosense Webster unit already is the exclusive distributor of Coherex Medical Inc.'s WaveCrest left atrial appendage occlusion system outside of the US, but the heart-rhythm device business now says it is acquiring the Coherex outright, expanding its commitment to the LAA closure space for reducing stroke in atrial fibrillation patients.
You may also be interested in...
Updated: J&J Will Pay At Least $400m For Laminar To Add Stroke-Stopping Technology
Currently available catheter-based devices for left-atrial appendage closure block the opening from the left atrium into the appendage, while Laminar’s innovative approach uses rotational motion to “eliminate” the LAA.
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.